Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

TargeGen selects TG-100435 for clinical development in oncology and edema

July 5, 2004

Novel antiangiogenic agents targeting Tie-2, VEGFR and/or Raf kinases

July 5, 2004

Kyowa Hakko returns to Geron Asian rights to telomerase inhibitors

July 5, 2004

Point Therapeutics commences last planned phase II studies for talabostat

July 5, 2004

CF-101 enters phase I study in solid tumor patients

July 5, 2004

PXD-101 enters phase I trial in hematologic cancer

July 2, 2004

Erbitux receives E.U. approval for metastatic colorectal cancer

July 2, 2004

Femara sNDA granted priority review by FDA

July 2, 2004

New IGF-1R inhibitors with potential in cancer therapy

July 2, 2004

Novel topoisomerase inhibitors identified by researchers at State U. of New Jersey

July 2, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.